ARCUTIS BIOTHERAPEUTICS, INC. Accretion Expense
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) reported Accretion Expense of $4.03 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-27.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AccretionExpense · last filed 2024-02-27
- ARCUTIS BIOTHERAPEUTICS, INC. accretion expense for fiscal 2023 was $4.03M, a 54.64% increase from fiscal 2022.
- ARCUTIS BIOTHERAPEUTICS, INC. accretion expense for fiscal 2022 was $2.61M.
- ARCUTIS BIOTHERAPEUTICS, INC. accretion expense for fiscal 2021 was $0.00.
- ARCUTIS BIOTHERAPEUTICS, INC. accretion expense for fiscal 2020 was $0.00.
| Period end | Accretion Expense 12 month |
|---|---|
| 2023-12-31 | $4.03M 10-K · filed 2024-02-27 |
| 2022-12-31 | $2.61M 10-K · filed 2024-02-27 |
| 2021-12-31 | $0.00 10-K · filed 2024-02-27 |
| 2020-12-31 | $0.00 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |